Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
This article was originally published in The Pink Sheet Daily
Executive Summary
OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.
You may also be interested in...
GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC
GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.
GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC
GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.
FDA's Risk Communications On Public Health Threats To Be Tested
Agency-sponsored focus groups will assess information about medical countermeasures; project builds on previous FDA efforts to understand consumer perceptions of risk communications.